PHATHOM PHARMACEUTICALS, INC. Operating Lease, Expense
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Operating Lease, Expense of $200.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2026-06-30 was $200.00K, a 33.33% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2026-03-31 was $200.00K, a 33.33% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2025-12-31 was $200.00K, a 33.33% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2025-09-30 was $200.00K, a 33.33% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. operating lease, expense for fiscal 2025 was $1.00M, a 9.09% decline from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. operating lease, expense for fiscal 2024 was $1.10M, a 0.00% change from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. operating lease, expense for fiscal 2023 was $1.10M, a 10.00% increase from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. operating lease, expense for fiscal 2022 was $1.00M, a 42.86% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $200.00K 10-Q · filed 2026-07-30 | $400.00K 10-Q · filed 2026-07-30 | $600.00K derived: sum of 3 quarters · filed 2026-07-30 | $800.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $200.00K 10-Q · filed 2026-04-30 | $400.00K derived: sum of 2 quarters · filed 2026-04-30 | $600.00K derived: sum of 3 quarters · filed 2026-04-30 | $900.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $400.00K derived: sum of 2 quarters · filed 2026-02-26 | $700.00K derived: sum of 3 quarters · filed 2026-07-30 | $1.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | $200.00K 10-Q · filed 2025-10-30 | $500.00K derived: sum of 2 quarters · filed 2026-07-30 | $800.00K 10-Q · filed 2025-10-30 | $1.10M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $300.00K 10-Q · filed 2026-07-30 | $500.00K 10-Q · filed 2026-07-30 | $900.00K derived: sum of 3 quarters · filed 2026-07-30 | $1.20M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $300.00K 10-Q · filed 2026-04-30 | $600.00K derived: sum of 2 quarters · filed 2026-04-30 | $900.00K derived: sum of 3 quarters · filed 2026-04-30 | $1.20M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $600.00K derived: sum of 2 quarters · filed 2026-02-26 | $900.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.10M 10-K · filed 2026-02-26 |
| 2024-09-30 | $300.00K 10-Q · filed 2025-10-30 | $600.00K derived: sum of 2 quarters · filed 2025-10-30 | $800.00K 10-Q · filed 2025-10-30 | $1.20M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $300.00K 10-Q · filed 2025-08-07 | $600.00K 10-Q · filed 2025-08-07 | $900.00K derived: sum of 3 quarters · filed 2025-08-07 | $1.20M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-01 | $600.00K derived: sum of 2 quarters · filed 2025-05-01 | $900.00K derived: sum of 3 quarters · filed 2025-05-01 | $1.20M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $600.00K derived: sum of 2 quarters · filed 2025-03-06 | $900.00K derived: sum of 3 quarters · filed 2025-03-06 | $1.10M 10-K · filed 2025-03-06 |
| 2023-09-30 | $300.00K 10-Q · filed 2024-11-07 | $600.00K derived: sum of 2 quarters · filed 2024-11-07 | $800.00K 10-Q · filed 2024-11-07 | $1.20M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $300.00K 10-Q · filed 2024-08-08 | $600.00K 10-Q · filed 2024-08-08 | $900.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.20M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $300.00K 10-Q/A · filed 2024-06-14 | $600.00K derived: sum of 2 quarters · filed 2024-06-14 | $900.00K derived: sum of 3 quarters · filed 2024-06-14 | $1.10M derived: sum of 4 quarters · filed 2024-06-14 |
| 2022-12-31 | $300.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | $600.00K derived: sum of 2 quarters · filed 2024-06-14 | $800.00K derived: sum of 3 quarters · filed 2024-06-14 | $1.00M 10-K/A · filed 2024-06-14 |
| 2022-09-30 | $300.00K 10-Q · filed 2023-11-09 | $500.00K derived: sum of 2 quarters · filed 2023-11-09 | $700.00K 10-Q · filed 2023-11-09 | $800.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $200.00K 10-Q · filed 2023-08-10 | $400.00K 10-Q · filed 2023-08-10 | $500.00K derived: sum of 3 quarters · filed 2023-08-10 | $700.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $200.00K 10-Q · filed 2023-05-10 | $300.00K derived: sum of 2 quarters · filed 2023-05-10 | $500.00K derived: sum of 3 quarters · filed 2023-05-10 | $700.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $100.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | $300.00K derived: sum of 2 quarters · filed 2023-02-28 | $500.00K derived: sum of 3 quarters · filed 2023-02-28 | $700.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | $200.00K 10-Q/A · filed 2022-11-09 | $400.00K derived: sum of 2 quarters · filed 2022-11-09 | $600.00K 10-Q/A · filed 2022-11-09 | $700.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $200.00K 10-Q · filed 2022-08-02 | $400.00K 10-Q · filed 2022-08-02 | $500.00K derived: sum of 3 quarters · filed 2022-08-02 | $700.00K derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $200.00K 10-Q · filed 2022-05-10 | $300.00K derived: sum of 2 quarters · filed 2022-05-10 | $500.00K derived: sum of 3 quarters · filed 2022-05-10 | $600.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $300.00K derived: sum of 2 quarters · filed 2022-03-01 | $400.00K derived: sum of 3 quarters · filed 2022-03-01 | $500.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $200.00K 10-Q · filed 2021-11-08 | $300.00K derived: sum of 2 quarters · filed 2021-11-08 | $400.00K 10-Q · filed 2021-11-08 | $451.00K derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $100.00K 10-Q · filed 2021-08-10 | $200.00K 10-Q · filed 2021-08-10 | $251.00K derived: sum of 3 quarters · filed 2021-08-10 | $251.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $100.00K 10-Q · filed 2021-05-11 | $151.00K derived: sum of 2 quarters · filed 2021-05-11 | $151.00K derived: sum of 3 quarters · filed 2021-05-11 | $151.00K derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $51.00K derived: sum of 2 quarters · filed 2021-03-30 | $51.00K derived: sum of 3 quarters · filed 2021-03-30 | $51.00K 10-K · filed 2021-03-30 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-10 | $0.00 derived: sum of 2 quarters · filed 2020-11-10 | $0.00 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |